Avelumab plus axitinib combination available via EAMS

It has just been announced that the avelumab plus axitinib combination has received positive scientific opinion for the Early Access to Medicines Scheme (EAMS) for the first-line treatment of advanced renal cell carcinoma (RCC). EAMS aims to give patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing […]

read more
Showing the single result